ATLANTA--(BUSINESS WIRE)--Inhibitex, Inc. (NASDAQ: INHX) announced today that a poster presentation describing preclinical data on INX-189, the lead compound from its HCV nucleotide polymerase inhibitor program, will be presented by Dr. Joseph M. Patti, Chief Scientific Officer and Senior Vice President of R&D, at the 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in Boston, MA. The full abstract can be viewed at the AASLD website at www.aasld.org.
